1. Karantanos T., Corn P.G., Thompson T.C. 2013. Prostate cancer progression after androgen deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 32, 5501–5511.
2. Wong Y.N., Ferraldeschi R., Attard G., de Bono J. 2014. Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat. Rev. Clin. Oncol. 11, 365–376.
3. Zobniw C.M., Causebrook A., Fong M.K. 2014. Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res. Rep. Urol. 6, 97–105.
4. El-Amm J., Patel N., Freeman A., Aragon-Ching J.B. 2013. Metastatic castration-resistant prostate cancer: Critical review of enzalutamide. Clin. Med. Insights Oncol. 7, 235–245.
5. Brasso K., Thomsen F.B., Schrader A.J., Schmid S.C., Lorente D., Retz M., Merseburger A.S., von Klot C.A., Boegemann M., de Bono J. 2014. Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: A multicentre analysis. Eur. Urol. pii S03022838(14)00680-0; doi 10.1016/j.eururo.2014.07.028